Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Almici, C
Right arrow Articles by Rizzoli, V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almici, C
Right arrow Articles by Rizzoli, V
Haematologica, Vol 80, Issue 5, 473-479
Copyright © 1995 by Ferrata Storti Foundation

Journal Article

Umbilical cord blood as a source of hematopoietic stem cells: from research to clinical application

C Almici, C Carlo-Stella, JE Wagner, and V Rizzoli

Department of Hematology, BMT Unit, University of Parma, Italy.

The clonogenic capacity of human umbilical cord blood (UCB) has been evaluated in several studies which found high numbers of primitive hematopoietic progenitor cells. Recently, UCB progenitor cells were shown to possess significant advantages over bone marrow (BM) in terms of proliferative capacity and immunologic reactivity. Therefore UCB has come to be considered an attractive source of hematopoietic stem cells for both research and clinical applications. UCB has been used in the treatment of diseases potentially curable by bone marrow transplantation (BMT). Seventy-one transplants have been performed world-wide using UCB cells, and the results have been reported to the International Cord Blood Transplant Registry (ICBTR). Since UCB cells appear to be less alloreactive than BM cells, studies have been carried out to determine the most successful procedures for collection and fractionation of UCB and to quantify precisely the progenitor/stem cell content. The different techniques for quantifying progenitor/stem cells as well as the results of related and unrelated UCB treatments will be reviewed. Further clinical applications of UCB involving gene therapy and stem cell expansion will be discussed.


This article has been cited by other articles:


Home page
 Stem CellsHome page
E.-S. Yoo, K.-E. Lee, J.-W. Seo, E.-H. Yoo, M.-A. Lee, S.-A. Im, Y.-C. Mun, S.-N. Lee, J.-W. Huh, M.-J. Kim, et al.
Adherent Cells Generated During Long-Term Culture of Human Umbilical Cord Blood CD34+ Cells Have Characteristics of Endothelial Cells and Beneficial Effect on Cord Blood Ex Vivo Expansion
Stem Cells, March 1, 2003; 21(2): 228 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Mao, G. Fu, J.-S. Wu, Q.-H. Zhang, J. Zhou, L.-X. Kan, Q.-H. Huang, K.-L. He, B.-W. Gu, Z.-G. Han, et al.
Identification of genes expressed in human CD34+ hematopoietic stem/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning
PNAS, July 7, 1998; 95(14): 8175 - 8180.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1995 by the Ferrata Storti Foundation.